` SIGA (SIGA Technologies Inc) vs S&P 500 Comparison - Alpha Spread

SIGA
vs
S&P 500

Over the past 12 months, SIGA has underperformed S&P 500, delivering a return of -14% compared to the S&P 500's 10% growth.

Stocks Performance
SIGA vs S&P 500

Loading
SIGA
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
SIGA vs S&P 500

Loading
SIGA
S&P 500
Difference
www.alphaspread.com

Performance By Year
SIGA vs S&P 500

Loading
SIGA
S&P 500
Add Stock

Competitors Performance
SIGA Technologies Inc vs Peers

S&P 500
SIGA
LLY
JNJ
NOVO B
ROG
Add Stock

SIGA Technologies Inc
Glance View

Market Cap
437.2m USD
Industry
Pharmaceuticals

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.

SIGA Intrinsic Value
29.66 USD
Undervaluation 79%
Intrinsic Value
Price
Back to Top